C. Huang

发表

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

B. Han, G. Jiang, H. Pan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

The clinical significance of splice variants and subcellular localisation of survivin in non-small cell lung cancers

R. Haba, D. Liu, M. Ueno, 2008, British Journal of Cancer.

E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer.

A. Yamauchi, D. Liu, C. Huang, 2001, The Annals of thoracic surgery.

Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT

M. Fukushima, H. Wada, D. Liu, 2006, British Journal of Cancer.

E2F1 overexpression associated with TS and survivin gene expressions in non-small cell lung cancer

D. Liu, M. Ueno, C. Huang, 2007 .

MRP-1/CD9 and KAI1/CD82 expression in normal and various cancer tissues.

M. Adachi, C. Huang, A. Takabayashi, 1997, International journal of oncology.

LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway.

C. Huang, L. Liu, S-Q Li, 2018, European review for medical and pharmacological sciences.

Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts

C. Huang, G. Yu, L. Ren-Heidenreich, 2014, British Journal of Cancer.

Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients.

N. Kohno, M. Adachi, C. Huang, 1998, The American journal of pathology.

Overexpression of bax associated with mutations in the loop-sheet-helix motif of p53.

N. Kohno, C. Huang, T. Taki, 1999, The American journal of pathology.

The tumour–stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients

R. Haba, D. Liu, M. Ueno, 2004, British Journal of Cancer.

Prognostic significance of angiogenesis in human pancreatic cancer

M. Adachi, C. Huang, Y. Nakajima, 1999, British Journal of Cancer.

Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KAI1/CD82 gene expression.

M. Higashiyama, M. Adachi, C. Huang, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increased expression of the lncRNA PVT1 is associated with poor prognosis in pancreatic cancer patients.

W. Yu, Q. Wang, C. Huang, 2015, Minerva medica.

The HAUSP gene plays an important role in non‐small cell lung carcinogenesis through p53‐dependent pathways

D. Liu, M. Ueno, C. Huang, 2006, The Journal of pathology.

Aberrant promoter hypermethylation of p16, survivin, and retinoblastoma in gastric cancer.

C. Huang, Q. Ji, L. Guo, 2017, Bratislavske lekarske listy.

Clinical application of biological markers for treatments of resectable non-small-cell lung cancers

R. Haba, D. Liu, M. Ueno, 2005, British Journal of Cancer.

Neural-cadherin expression associated with angiogenesis in non-small-cell lung cancer patients

D. Liu, C. Huang, D. Masuya, 2003, British Journal of Cancer.

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).

Yi-long Wu, Y. Wu, C. Zhou, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

G. Breithardt, H. Crijns, P. Mclaughlin, 2016, Journal of the American Heart Association.

Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) (INFORM; C-TONG 0804).

M. Wang, X. Liu, Y. Cheng, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High Expression of Nuclear Factor of Activated T Cells in Chinese Primary Non-Small Cell Lung Cancer Tissues

S. Shi, F. Zhou, K. Shao, 2007 .

High expression of nuclear factor of activated T cells in Chinese primary non-small cell lung cancer tissues.

Z Chen, S. Shi, F. Zhou, 2007, The International journal of biological markers.

M. Wang, X. Liu, Y. Cheng, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung neuroendocrine cancer (NEC).

D. Gandara, R. Doebele, D. Camidge, 2010 .

Impact of metabolic syndrome on the survival of Chinese patients with resectable esophageal squamous cell carcinoma.

C. Huang, P. Lin, T. Rong, 2016, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

A phase II study (CTONG0803) of erlotinib as second-line treatment in advanced non-small cell lung cancer (NSCLC) patients (pts) with asymptomatic brain metastases (BM) after first-line chemotherapy (CT).

Y. Wu, C. Zhou, S. Lu, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.